Progression-free survival in patients with ⁶⁸Ga-PSMA-PET-directed SBRT for lymph node oligometastases

References

• Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–453.
   PubMed Web of Science ®Google Scholar
• Phillips R, Yue Shi W, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650–659.
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase ii randomized trial. J Clin Oncol. 2020;38(25):2830–2838.
   PubMed Web of Science ®Google Scholar
• Fodor A, Lancia A, Ceci F, et al. Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row: nodal oligorecurrent prostate cancer. World J Urol. 2019;37(12):2607–2613.
   PubMed Web of Science ®Google Scholar
• Moghul M, Somani B, Lane T, et al. Detection rates of recurrent prostate cancer: 68 Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET/CT scans. A systematic review. Ther Adv Urol. 2019;11:175628721881579.
   Web of Science ®Google Scholar
• Mazzola R, Francolini G, Triggiani L, et al. Metastasis-directed therapy (SBRT) guided by PET-CT 18 F-CHOLINE Versus PET-CT 68 Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness. Clin Genitourin Cancer. 2021;19(3):230–236.
   PubMed Web of Science ®Google Scholar
• Kneebone A, Hruby G, Ainsworth H, et al. Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography. Eur Urol Oncol. 2018;1(6):531–537.
   PubMed Web of Science ®Google Scholar
• Artigas C, Flamen P, Charlier F, et al. 68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy. World J Urol. 2019;37(8):1535–1542.
   PubMed Web of Science ®Google Scholar
• Ong WL, Koh TL, Joon DL, et al. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature. BJU Int. 2019;124(Suppl 1):19–30.
   PubMed Web of Science ®Google Scholar
• Hurmuz P, Onal C, Ozyigit G, et al. Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002). Strahlenther Onkol. 2020;196(11):1034–1043.
   PubMed Web of Science ®Google Scholar
• Kalinauskaite G, Senger C, Kluge A, et al. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer. PLOS One. 2020;15(10):e0240892.
   PubMed Web of Science ®Google Scholar
• Marzec J, Becker J, Paulsen F, et al. 68Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery. Acta Oncol. 2020;59(2):149–156.
   PubMed Web of Science ®Google Scholar
• Deek MP, Yu C, Phillips R, et al. Radiation therapy in the definitive management of oligometastatic prostate cancer: the Johns Hopkins experience. Int J Radiat Oncol Biol Phys. 2019;105(5):948–956.
   PubMed Web of Science ®Google Scholar
• Chaw CL, deSouza NM, Khoo V, et al. Clinical outcomes of stereotactic body radiotherapy with immediate versus delayed hormone therapy in men with oligometastatic recurrence of prostate cancer. Clin Oncol. 2020;32(8):509–517.
   Web of Science ®Google Scholar
• Kroeze SGC, Henkenberens C, Schmidt-Hegemann NS, et al. Prostate-specific membrane antigen positron emission tomography-detected oligorecurrent prostate cancer treated with metastases-directed radiotherapy: role of addition and duration of androgen deprivation. Eur Urol Focus. 2021;7(2):309–316.
   PubMedGoogle Scholar
• Nguyen PL, Alibhai SMH, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–836.
   PubMed Web of Science ®Google Scholar
• Fossati N, Suardi N, Gandaglia G, et al. Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis. Eur Urol. 2019;75(1):176–183.
   PubMed Web of Science ®Google Scholar
• Pitroda SP, Khodarev NN, Huang L, et al. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018;9(1):1793.
   PubMed Web of Science ®Google Scholar
• Dhondt B, De Bleser E, Claeys T, et al. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time. World J Urol. 2019;37(12):2557–2564.
   PubMed Web of Science ®Google Scholar
• Werensteijn-Honingh AM, Kroon PS, Winkel D, et al. Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: multi-fraction treatment of pelvic lymph node oligometastases. Radiother Oncol. 2019;134:50–54.
   PubMed Web of Science ®Google Scholar
• Werensteijn-Honingh AM, Jürgenliemk-Schulz IM, Gadellaa-Van Hooijdonk CG, et al. Impact of a vacuum cushion on intrafraction motion during online adaptive MR-guided SBRT for pelvic and para-aortic lymph node oligometastases. Radiother Oncol. 2021;154:110–117.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Smets EM, Garssen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI): psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315–325.
   PubMed Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–1736.
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18-28–e28.
   Web of Science ®Google Scholar
• Arlen PM, Bianco F, Dahut WL, Prostate Specific Antigen Working Group, et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008;179(6):2181–2186.
   PubMed Web of Science ®Google Scholar
• Poon I, Erler D, Dagan R, et al. Evaluation of definitive stereotactic body radiotherapy and outcomes in adults with extracranial oligometastasis. JAMA Netw Open. 2020;3(11):e2026312.
   PubMed Web of Science ®Google Scholar
• Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594.
   PubMed Web of Science ®Google Scholar
• Heinze G, Wallisch C, Dunkler D. Variable selection – a review and recommendations for the practicing statistician. Biom J. 2018;60(3):431–449.
   PubMed Web of Science ®Google Scholar
• Harrell FE, Jr Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med. 1996;15(4):361–387.
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Fanetti G, Fodor C, et al. Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer. 2017;15(4):e623–e632.
   PubMed Web of Science ®Google Scholar
• Nicosia L, Franzese C, Mazzola R, et al. Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. Strahlenther Onkol. 2020;196(3):213–221.
   PubMed Web of Science ®Google Scholar
• De Bleser E, Jereczek-Fossa BA, Pasquier D, et al. Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy. Eur Urol. 2019;76(6):732–739.
   PubMed Web of Science ®Google Scholar
• Wallis CJD, Saskin R, Choo R, et al. Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(1):21–30.
   PubMed Web of Science ®Google Scholar
• Neal DE, Metcalfe C, Donovan JL, ProtecT Study Group, et al. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the Protect Randomised Controlled Trial according to treatment received. Eur Urol. 2020;77(3):320–330.
   PubMed Web of Science ®Google Scholar
• De Bruycker A, Spiessens A, Dirix P, et al. PEACE V – salvage treatment of oligorecurrent nodal prostate cancer metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer. 2020;20(1):406.
   PubMed Web of Science ®Google Scholar
• Murthy V, Maitre P, Kannan S, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. 2021;39(11):1234–1242.
   PubMed Web of Science ®Google Scholar
• Bravi CA, Fossati N, Gandaglia G, et al. Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought. Eur Urol. 2020;78(5):661–669.
   PubMed Web of Science ®Google Scholar
• Tunn UW, Canepa G, Kochanowsky A, et al. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2012;15(3):296–302.
   PubMed Web of Science ®Google Scholar
• Langenhuijsen JF, Badhauser D, Schaaf B, et al. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol. 2013;31(5):549–556.
   PubMed Web of Science ®Google Scholar